Amends Agreement for Immunosuppressive Drug August 29, 2007 – Aspreva, a Canadian biotech, will underwrite part of the costs that Roche incurs for its clinical work in China on CellCept as a treatment for lupus nephritis. As a result of the changes, Aspreva will take a $20 million charge in the third quarter. In 2003, Roche out-licensed to Aspreva the rights to develop CellCept as a treatment for autoimmune disorders (except in Japan). From the start, lupus nephritis was a prime target, although other autoimmune diseases are also under consideration. More details...
